Infectious Disease Deals Up 2400% in 2026 — The Data
Infectious disease deal activity exploded 2400% between the first and second halves of the May 2025–November 2026 window, jumping from 1 deal to 25. Gilead, Lilly, and Ferring are leading the charge. Here's what's driving it and what it means for your next term sheet.
Twenty-five infectious disease deals closed between May 10 and November 10, 2026 — a 2,400% increase over the single deal recorded in the prior six-month window (November 10, 2025 to May 10, 2026). This is not a statistical artifact from a low base. This is a category-wide re-entry by Big Pharma into a therapeutic area that most BD teams had deprioritized since the post-COVID hangover bottomed out in late 2024. The driver is structural: antimicrobial resistance (AMR) has reached a regulatory and reimbursement inflection point, and pipeline gaps in hepatitis B, respiratory viruses, and novel antibiotics are now urgent enough to move deal committees.
The Data — Infectious Disease Deal Activity, Period over Period
| Period | Value |
|---|---|
| 2025-11-10 to 2026-05-10 | 1 |
| 2026-05-10 to 2026-11-10 | 25 |
| Change | +2400.0% |
Yes, the base period was unusually thin — a single transaction across six months. But that drought itself was the signal. Infectious disease licensing 2026 has snapped back with a velocity that outpaces every other therapeutic area shift we've tracked on Deal Benchmarks this year, including the well-documented GLP-1 adjacency land-grab in metabolic disease. When a category goes from near-zero to 25 deals in one half, something fundamental has changed in how acquirers are valuing the space.
What's Driving the Trend
Regulatory tailwinds are real and accelerating. The FDA's updated guidance on streamlined clinical trial designs for novel antibiotics — issued in Q1 2026 — materially reduced Phase 3 program costs for drugs targeting WHO priority pathogens. The PASTEUR Act reauthorization in the U.S. and the EU's parallel pull-incentive framework finally gave pharma finance teams a reimbursement floor they could model against. For the first time in a decade, infectious disease assets have predictable revenue trajectories that satisfy internal rate-of-return thresholds at large pharma companies. That single policy change unlocked more BD activity than any scientific breakthrough.
Pipeline gaps are acute. Gilead's HBV franchise faces genericization risk. Lilly has a well-documented hole in anti-infectives. GSK's pandemic-era respiratory vaccine portfolio needs next-generation boosters. These aren't speculative gaps — they're line-item problems on 2028–2030 revenue projections that every analyst on the Street is flagging. When three or more large-cap pharma companies are simultaneously hunting in the same therapeutic area, deal velocity spikes. That's exactly what happened here.
Capital structure matters too. Biotech funding in infectious disease rebounded in mid-2026 after Series B and C rounds for companies like Assembly Biosciences and Amplitude Therapeutics gave them clinical-stage leverage. Well-capitalized biotechs don't need to accept predatory terms. That dynamic forces buyers to move faster and pay more — or risk losing assets to competitors. The 25-deal surge reflects a competitive auction environment, not a buyer's market.
Notable Deals
| Licensor | Licensee | Upfront | TDV | Date |
|---|---|---|---|---|
| Amplitude Therapeutics | Eli Lilly | — | — | 2026-09-23 |
| Assembly Biosciences | Gilead Sciences | $75M | — | 2026-09-08 |
| Ferring Pharmaceuticals | RedHill Biopharma | $12M | — | 2026-09-01 |
| GC Biopharma | Osivax | — | — | 2026-08-27 |
| Nona Biosciences | Medical University of Vienna | — | — | 2026-07-22 |
Assembly Biosciences–Gilead ($75M upfront) is the anchor deal in this cycle. Gilead paid a premium upfront for Assembly's HBV assets — consistent with Gilead's pattern of building franchise depth through in-licensing rather than internal R&D alone. A $75M upfront for a clinical-stage HBV program is at the upper end of historical comps in this space, signaling that Gilead sees genuine scarcity value. Compare this with HBV deal upfronts from 2022–2024, which averaged closer to $30–45M for similar-stage assets per Deal Benchmarks data.
Amplitude Therapeutics–Eli Lilly is the more strategically interesting transaction. Lilly has no meaningful infectious disease franchise. This deal — terms undisclosed — signals a deliberate portfolio expansion, not gap-filling. Watch Lilly closely for follow-on deals in 2027. Companies that make one infectious disease acquisition rarely stop at one.
Ferring–RedHill ($12M upfront) represents the other end of the spectrum: a mid-sized specialty pharma play in GI-adjacent infectious disease. The $12M upfront is modest, but RedHill's microbiome-focused pipeline gives Ferring a platform, not just a product. This deal structure — small upfront, likely milestone-heavy — is the model for sub-$50M infectious disease licensing 2026.
The GC Biopharma–Osivax and Nona Biosciences–Medical University of Vienna deals are earlier-stage and undisclosed in financial terms, but they point to a broadening of deal activity beyond the usual U.S.-centric pharma acquirers. Asian and European partners are moving into the space, which adds competitive pressure and validates the trend's durability.
What This Means for BD Teams Right Now
If you're selling infectious disease assets, this is your window. Twenty-five deals in six months creates a pricing environment where buyers are competing. Upfronts are trending higher. The Assembly–Gilead $75M upfront will become the new anchor for clinical-stage HBV and antiviral negotiations. Use it. If you have a differentiated AMR, HBV, or respiratory virus asset at Phase 1b or later, you should be running a structured process with at least three potential acquirers.
If you're buying, move now — not next quarter. The infectious disease deal trends 2026 data is clear: velocity is increasing, not plateauing. Waiting for Q1 2027 means competing against pharma companies that have already staffed up their anti-infective BD teams and have board-approved search mandates. The cost of delay is not just price escalation — it's losing access to the best assets entirely.
Deal structures are shifting. We're seeing higher upfronts as a percentage of total deal value, compressed milestone schedules, and more co-development/co-commercialization rights retained by licensors. Earn-out-heavy structures that dominated 2023–2024 infectious disease deals are losing favor with well-capitalized biotechs that have alternatives. If your standard term sheet leads with a $5M upfront and back-loaded milestones, you will lose to competitors offering $20M+ upfront with cleaner structures. Run your proposed terms through Solidus before your next negotiation to see where you sit relative to these new benchmarks.
Benchmark your deal against current market rates. The infectious disease deal landscape has repriced in six months. Whether you're structuring an out-license, evaluating an inbound term sheet, or building a competitive analysis for your board, you need current comps — not 2024 data. Use the Ambrosia calculator to stress-test your deal economics against the 25 transactions that have reshaped this market.
More from the Blog
Immunology Deals Up 1167% in 2026 — Here's the Data
Immunology deal activity jumped from 3 transactions to 38 in just six months — a 1167% increase that signals a fundamental shift in Big Pharma portfolio strategy. We break down the deals, the drivers, and what BD teams should do right now.
Market TrendRadiopharm Deals Are Up 1200% in 2026 — Here's the Data
Radiopharm deal activity surged 1200% in the six months ending November 2026, jumping from zero deals to 12. The Telix-ITM megadeal at $2.35B TDV and Novartis's $900M Boomray bet signal that Big Pharma's radiopharmaceutical arms race is no longer a hypothesis — it's a balance sheet reality.
Market TrendNeurology Deals Are Up 1325% in 2026 — Here's the Data
Neurology licensing activity exploded from 4 deals to 57 in six months — a 1325% increase that reshapes the competitive landscape. The Lilly-Atai/Beckley megadeal signals where the capital is flowing, and BD teams need to recalibrate fast.
Deal Intelligence
Ready to Benchmark Your Deal?
Get instant, data-driven deal terms powered by 1,400+ verified biopharma transactions across 12 therapeutic areas.